Humoral immune response in healthcare workers after two doses of a BNT162b2 mRNA vaccine in Yucatan, Mexico

被引:2
|
作者
Figueroa-Hurtado, Esperanza [1 ]
Ortiz-Farias, Diana Lizbeth [1 ]
Sada-Ovalle, Isabel [2 ]
Maldonado-Ortiz, Sandra Yareth [3 ]
Valdivieso-Jimenez, Jorge Arturo [4 ]
Cortes-Telles, Arturo [1 ]
机构
[1] Hosp Reg Alta Especialidad Peninsula Yucatan, Dept Neumol & Cirugia Torax, Calle 7-433 20 22,Fraccionamiento Altabrisa, Merida 97133, Mexico
[2] Univ Autonoma San Luis Potosi, Fac Med, Dept Fisiol, San Luis Potosi, San Luis Potosi, Mexico
[3] Hosp Reg Alta Especialidad Peninsula Yucatan, Unidad Cuidados Intensivos, Merida, Mexico
[4] Hosp Reg Alta Especialidad Peninsula Yucatan, Unidad Atenc COVID19, Merida, Mexico
来源
RESPIROLOGY CASE REPORTS | 2022年 / 10卷 / 04期
关键词
COVID-19; humoral immunity; immune response; vaccine;
D O I
10.1002/rcr2.920
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as the host immune response after vaccination and viral infection have shown to be highly heterogeneous. This is a case series study analysing humoral immune response and vaccination side effects after two doses of a BNT162b2 mRNA among healthcare workers (HCWs) in Mexico. All participants were scheduled for their two doses of mRNA BNT162b2 vaccine and provided information through a questionnaire: demographic characteristics, antibody serum titres and vaccination-related side effects. Blood samples were obtained for serology testing after the first and second doses of vaccine. No serious adverse effects due to vaccination were reported; nonetheless, non-medical HCWs reported more side effects after the second dose. The previous infection with SARS-CoV-2 boosted immune response after receiving the first vaccination (roughly 30 times higher than those without previous infection); nonetheless, after the second dose, the immune response did not show a higher titre as might be expected.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Durability of immune responses to the BNT162b2 mRNA vaccine
    Suthar, Mehul S.
    Arunachalam, Prabhu S.
    Hu, Mengyun
    Reis, Noah
    Trisal, Meera
    Raeber, Olivia
    Chinthrajah, Sharon
    Davis-Gardner, Meredith E.
    Manning, Kelly
    Mudvari, Prakriti
    Boritz, Eli
    Godbole, Sucheta
    Henry, Amy R.
    Douek, Daniel C.
    Halfmann, Peter
    Kawaoka, Yoshihiro
    Boyd, Scott D.
    Davis, Mark M.
    Zarnitsyna, Veronika I.
    Nadeau, Kari
    Pulendran, Bali
    MED, 2022, 3 (01): : 25 - 27
  • [22] Humoral and cellular Immune Response after a Single Dose of BNT162b2
    Krome, Susanne
    TRANSFUSIONSMEDIZIN, 2021, 11 (04) : 217 - 218
  • [23] Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study
    Herzberg, Jonas
    Fischer, Bastian
    Lindenkamp, Christopher
    Becher, Heiko
    Becker, Ann-Kristin
    Honarpisheh, Human
    Guraya, Salman Yousuf
    Strate, Tim
    Knabbe, Cornelius
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [24] Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence
    Daungsupawong, H.
    Wiwanitkit, V.
    MEDICINA DE FAMILIA-SEMERGEN, 2024, 50 (04):
  • [25] Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses
    Chang, Amy
    Chiang, Teresa PY.
    Kim, Jake D.
    Mitchell, Jonathan
    Alejo, Jennifer L.
    Jefferis, Alexa A.
    Avery, Robin K.
    Tobian, Aaron A. R.
    Levan, Macey L.
    Warren, Daniel S.
    Garonzik-Wang, Jacqueline M.
    Massie, Allan B.
    Segev, Dorry L.
    Werbel, William A.
    CLINICAL TRANSPLANTATION, 2022, 36 (08)
  • [26] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers
    Rojkovich, Bernadette
    Nemeth, Dora
    Torok, Eszter
    Szabo, Bernadette
    Pinter, Agnes
    Juhasz, Istvan
    Weidl, Marton
    Lanyi, Eva
    Pavel-Szecsko, Judit
    Lazar, Imre
    Perduk, Andras
    Reiter, Jozsef
    Nagy, Gyorgy
    Nagy, Erzsebet
    Geher, Pal
    ORVOSI HETILAP, 2021, 162 (39) : 1551 - 1557
  • [27] Relapses of Immune Thrombocytopenia after the second and booster doses of BNT162b2 Vaccine
    Ratajczak-Enselme, Maja
    Mutoni, Guy-Clebert
    Demeules, Jules
    Favet, Laurence
    Ing Lorenzini, Kuntheavy
    ACTA HAEMATOLOGICA, 2023, 146 (01) : 52 - 57
  • [28] Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers
    Nunez Lopez, Concepcion
    Manuel Gonzalez de Abreu, Juan
    Perez-Blanco, Veronica
    de Miguel Buckley, Rosa
    Romero Gomez, Maria Pilar
    Diaz-Menendez, Marta
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2023, 41 (01): : 33 - 35
  • [29] Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
    Bader, Guy
    Itan, Michal
    Edry-Botzer, Liat
    Cohen, Hadar
    Haskin, Orly
    Mozer-Glassberg, Yael
    Harel, Liora
    Munitz, Ariel
    Mandelblit, Nufar Marcus
    Gerlic, Motti
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [30] Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine
    Tani, Naoki
    Chong, Yong
    Kurata, Yasuo
    Gondo, Kei
    Oishi, Ryo
    Goto, Takeyuki
    Minami, Junya
    Onozawa, Kyoko
    Nagano, Sukehisa
    Shimono, Nobuyuki
    Ikematsu, Hideyuki
    Kuwano, Hiroyuki
    VACCINE, 2022, 40 (13) : 2062 - 2067